Literature DB >> 28754674

Adipose Progenitor Cell Secretion of GM-CSF and MMP9 Promotes a Stromal and Immunological Microenvironment That Supports Breast Cancer Progression.

Francesca Reggiani1, Valentina Labanca1, Patrizia Mancuso1, Cristina Rabascio1, Giovanna Talarico1, Stefania Orecchioni1, Andrea Manconi2, Francesco Bertolini3.   

Abstract

A cell population with progenitor-like phenotype (CD45-CD34+) resident in human white adipose tissue (WAT) is known to promote the progression of local and metastatic breast cancer and angiogenesis. However, the molecular mechanisms of the interaction have not been elucidated. In this study, we identified two proteins that were significantly upregulated in WAT-derived progenitors after coculture with breast cancer: granulocyte macrophage colony-stimulating factor (GM-CSF) and matrix metallopeptidase 9 (MMP9). These proteins were released by WAT progenitors in xenograft and transgenic breast cancer models. GM-CSF was identified as an upstream modulator. Breast cancer-derived GM-CSF induced GM-CSF and MMP9 release from WAT progenitors, and GM-CSF knockdown in breast cancer cells neutralized the protumorigenic activity of WAT progenitors in preclinical models. GM-CSF neutralization in diet-induced obese mice significantly reduced immunosuppression, intratumor vascularization, and local and metastatic breast cancer progression. Similarly, MMP9 inhibition reduced neoplastic angiogenesis and significantly decreased local and metastatic tumor growth. Combined GM-CSF neutralization and MMP9 inhibition synergistically reduced angiogenesis and tumor progression. High-dose metformin inhibited GM-CSF and MMP9 release from WAT progenitors in in vitro and xenograft models. In obese syngeneic mice, metformin treatment mimicked the effects observed with GM-CSF neutralization and MMP9 inhibition, suggesting these proteins as new targets for metformin. These findings support the hypothesis that GM-CSF and MMP9 promote the protumorigenic effect of WAT progenitors on local and metastatic breast cancer. Cancer Res; 77(18); 5169-82. ©2017 AACR. ©2017 American Association for Cancer Research.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28754674     DOI: 10.1158/0008-5472.CAN-17-0914

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  27 in total

1.  Relationship between matrix metalloproteinase-9 and some clinicopathological prognostic factors of breast carcinoma.

Authors:  Fereshteh Mohammadizadeh; Mahsa Bagherian-Dehkordia
Journal:  Am J Clin Exp Immunol       Date:  2021-02-15

2.  Cancer Stem Cells: An Ever-Hiding Foe.

Authors:  Jacek R Wilczyński
Journal:  Exp Suppl       Date:  2022

3.  [Talin1 is highly expressed in the fallopian tube and chorionic villi to promote trophoblast invasion in tubal pregnancy].

Authors:  P Qiu; X Lin; G Deng
Journal:  Nan Fang Yi Ke Da Xue Xue Bao       Date:  2022-04-20

Review 4.  GM-CSF: A Double-Edged Sword in Cancer Immunotherapy.

Authors:  Anil Kumar; Adeleh Taghi Khani; Ashly Sanchez Ortiz; Srividya Swaminathan
Journal:  Front Immunol       Date:  2022-07-05       Impact factor: 8.786

5.  Breast cancer-derived GM-CSF regulates arginase 1 in myeloid cells to promote an immunosuppressive microenvironment.

Authors:  Xinming Su; Yalin Xu; Gregory C Fox; Jingyu Xiang; Kristin A Kwakwa; Jennifer L Davis; Jad I Belle; Wen-Chih Lee; Wing H Wong; Francesca Fontana; Leonel F Hernandez-Aya; Takayuki Kobayashi; Helen M Tomasson; Junyi Su; Suzanne J Bakewell; Sheila A Stewart; Christopher Egbulefu; Partha Karmakar; Melisa A Meyer; Deborah J Veis; David G DeNardo; Gregory M Lanza; Samuel Achilefu; Katherine N Weilbaecher
Journal:  J Clin Invest       Date:  2021-10-15       Impact factor: 14.808

6.  Bone marrow niche-derived extracellular matrix-degrading enzymes influence the progression of B-cell acute lymphoblastic leukemia.

Authors:  Divij Verma; Costanza Zanetti; Parimala Sonika Godavarthy; Rahul Kumar; Valentina R Minciacchi; Jakob Pfeiffer; Markus Metzler; Sylvain Lefort; Véronique Maguer-Satta; Franck E Nicolini; Barbara Burroni; Michaela Fontenay; Daniela S Krause
Journal:  Leukemia       Date:  2020-01-09       Impact factor: 11.528

7.  Vinorelbine, cyclophosphamide and 5-FU effects on the circulating and intratumoural landscape of immune cells improve anti-PD-L1 efficacy in preclinical models of breast cancer and lymphoma.

Authors:  Stefania Orecchioni; Giovanna Talarico; Valentina Labanca; Angelica Calleri; Patrizia Mancuso; Francesco Bertolini
Journal:  Br J Cancer       Date:  2018-04-26       Impact factor: 7.640

8.  Methods to Evaluate Cell Growth, Viability, and Response to Treatment in a Tissue Engineered Breast Cancer Model.

Authors:  Kayla F Goliwas; Jillian R Richter; Hawley C Pruitt; Lita M Araysi; Nicholas R Anderson; Rajeev S Samant; Susan M Lobo-Ruppert; Joel L Berry; Andra R Frost
Journal:  Sci Rep       Date:  2017-10-26       Impact factor: 4.379

9.  Serum markers improve current prediction of metastasis development in early-stage melanoma patients: a machine learning-based study.

Authors:  Filippo Mancuso; Sergio Lage; Javier Rasero; José Luis Díaz-Ramón; Aintzane Apraiz; Gorka Pérez-Yarza; Pilar Ariadna Ezkurra; Cristina Penas; Ana Sánchez-Diez; María Dolores García-Vazquez; Jesús Gardeazabal; Rosa Izu; Karmele Mujika; Jesús Cortés; Aintzane Asumendi; María Dolores Boyano
Journal:  Mol Oncol       Date:  2020-06-24       Impact factor: 6.603

10.  Predictive and prognostic value of Matrix metalloproteinase (MMP) - 9 in neoadjuvant chemotherapy for triple-negative breast cancer patients.

Authors:  Ruo-Xi Wang; Sheng Chen; Liang Huang; Zhi-Ming Shao
Journal:  BMC Cancer       Date:  2018-09-21       Impact factor: 4.430

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.